Inborn Errors of Metabolism

Metabolism is a network of pathways — sequences of reactions, each catalysed by a specific enzyme, converting one molecule into the next. An inborn error of metabolism (IEM) is a genetic condition in which one of these enzymes is missing or doesn't work properly, usually due to an inherited mutation in the gene that codes for it. Picture a metabolic pathway as a series of locks on a canal, each needing a specific key (enzyme) to open. If one lock is broken: - The substrate — the molecule that should have been processed by the faulty enzyme — builds up to abnormally high levels upstream of the block. If it (or something derived from it via an alternative pathway) is toxic at high concentrations, it can directly damage tissue, especially the brain. - The product the faulty enzyme should have made is deficient. If that product is essential — for energy production, for building another important molecule, or as a hormone precursor — its absence causes problems of its own. Most inborn errors of metabolism are inherited in an autosomal recessive pattern: a person needs a non-functional copy of the gene from *both* parents to be affected. Carrier parents (with one working copy) are usually completely healthy, but if two carriers have children, each child has a 1 in 4 chance of inheriting both faulty copies. This is why these conditions, while individually rare, are collectively significant.

Phenylketonuria (PKU) is the textbook inborn error of metabolism, and it illustrates the general principles that apply to many similar conditions. The defect: PKU is caused by deficiency of the enzyme phenylalanine hydroxylase, which normally converts the amino acid phenylalanine into another amino acid, tyrosine. The consequences: - Build-up of phenylalanine — obtained from dietary protein, it accumulates to very high levels in the blood. At these concentrations, phenylalanine (and its derivatives) is toxic to the developing brain. Left untreated, this causes severe, irreversible intellectual disability. - Deficiency of tyrosine — normally an important amino acid, the starting material for the pigment melanin and several neurotransmitters. The body can obtain some tyrosine from diet directly, but the blocked pathway still contributes to the overall picture. Why newborn screening matters: babies with PKU appear completely normal at birth, because phenylalanine has been cleared by the mother's metabolism during pregnancy. Damage begins only after birth, once the baby starts feeding and processing protein independently. This is why virtually every country performs newborn screening — a heel-prick blood sample taken in the first days of life — specifically to catch PKU and similar conditions before symptoms begin. Treatment is primarily dietary: a lifelong diet very low in phenylalanine, avoiding high-protein foods, while still supplying enough phenylalanine for essential needs. PKU is a striking example of how understanding the precise biochemical defect leads directly to a simple, effective treatment — long before gene-based therapies were possible.

Inborn errors can affect carbohydrate metabolism just as they affect amino acid metabolism — with consequences for both energy availability and specific organs. Galactosemia: Galactose is a sugar obtained mainly from lactose, the sugar in milk (lactose splits into glucose and galactose during digestion). In classic galactosemia, an enzyme needed to process galactose further is deficient, so galactose and related compounds accumulate. - Effects: accumulated galactose is toxic to the liver, kidneys, brain, and eyes (where it can cause cataracts). Affected babies become severely unwell within days of starting milk feeds, with feeding difficulties, jaundice, and liver damage. - Treatment: like PKU, a lifelong galactose-free (and therefore lactose-free) diet — removing the substrate the body can't process. Also caught by newborn screening in many countries. Glycogen storage diseases (GSDs): Glycogen is the body's storage form of glucose, built up in liver and muscle and broken down when blood glucose is needed. Several inborn errors affect the enzymes that build or break down glycogen — each numbered type (e.g. GSD type I, "von Gierke disease") hits a different enzyme in the pathway. A common theme: when the enzyme needed to release glucose from glycogen is missing, glycogen accumulates abnormally in the liver (which enlarges) while the body simultaneously *cannot* maintain normal blood glucose between meals — too much storage, too little available fuel, because the store can't be accessed. Management often involves frequent feeding (including, for some types, a slow-release cornstarch preparation) to prevent dangerous drops in blood glucose between meals. | Condition | Enzyme affected | What accumulates | Typical management | |---|---|---|---| | Phenylketonuria | Phenylalanine hydroxylase | Phenylalanine (toxic to the brain) | Lifelong low-phenylalanine diet | | Galactosemia | Galactose-processing enzyme | Galactose (toxic to liver, kidneys, brain, eyes) | Lifelong galactose-free diet | | Glycogen storage disease | Glycogen-metabolising enzyme | Glycogen in liver/muscle | Frequent feeding; slow-release cornstarch |

The urea cycle is the pathway by which the body converts ammonia — a toxic by-product of breaking down amino acids — into urea, a much less toxic compound safely excreted by the kidneys in urine. The defect: urea cycle disorders arise from deficiency in any one of several urea cycle enzymes. Whichever enzyme is affected, the consequence is the same: ammonia that should have become urea instead accumulates in the blood, a state called hyperammonaemia. Why ammonia is so dangerous: it is highly toxic to the brain even at modest elevations, disrupting energy production within brain cells and interfering with neurotransmitter signalling. Severe hyperammonaemia causes confusion, vomiting, and lethargy progressing to coma, and can cause permanent brain damage or death if untreated — making urea cycle disorders medical emergencies whenever ammonia rises significantly, whether from the underlying genetic condition or, in milder cases, triggered by illness or excessive protein intake overwhelming the pathway's limited remaining capacity. Management principles: - Reducing protein intake limits the ammonia generated from amino acid breakdown in the first place - Medications providing alternative nitrogen-excretion routes help dispose of excess nitrogen without relying on the blocked step - During acute episodes (often triggered by infection, which increases protein breakdown), urgent treatment — sometimes including dialysis to physically remove ammonia from the blood — may be needed to prevent permanent brain injury Urea cycle disorders show how a single blocked step in a *detoxification* pathway — not an energy-producing one — can still be immediately life-threatening, because the accumulating substance is directly and rapidly toxic to the brain.

Although individual inborn errors of metabolism are each rare, collectively they affect a meaningful number of people, and the principles behind diagnosing and managing them illustrate broader themes in medicine. Newborn screening programmes: many countries screen every newborn for a panel of treatable inborn errors using a small blood sample. The conditions chosen generally share three features — they are serious if untreated, essentially silent at birth (so can't be spotted just by examining the baby), and critically, have an effective treatment available if started early. That last point is what makes screening worthwhile: for PKU, galactosemia, and several other conditions, early detection genuinely prevents lifelong disability. Diagnosis in older children and adults: not every inborn error is caught by newborn screening. Some are milder and present later in life, sometimes triggered by illness, fasting, or a dietary change that "unmasks" a previously unnoticed metabolic limitation. Diagnosis often involves measuring specific metabolites in blood or urine — an abnormally high substrate level, or a low product level, points to a specific enzyme defect. Beyond diet — emerging treatments: - Enzyme replacement therapy provides a working version of the missing enzyme directly (used for some lysosomal storage disorders) - Gene therapy aims to correct the underlying genetic defect itself, building on the gene-editing tools you met in the molecular biology techniques lesson Inborn errors of metabolism bring together genetics, biochemistry, and clinical medicine in a uniquely direct way: a single mutated gene, a single faulty enzyme, a single blocked reaction — and from that one molecular event, a cascade of consequences for the whole body. Understanding the biochemistry doesn't just explain the disease; for many of these conditions, it directly *is* the treatment.